(Q36569744)

15 August 2017

1 reference

title

New developments in the treatment of chronic hepatitis B. (English)

1 reference

15 August 2017

1 reference

Stephanos J Hadziyannis

series ordinal

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

913-921

1 reference

Hepatitis B: an important public health issue

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Review article: current management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Emerging treatments in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

The maze of treatments for hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Hepatitis B--preventable and now treatable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

AASLD 2005 distinguished achievement award to Dr. Jenny Heathcote.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Regulated vesicle trafficking of membrane transporters in hepatic epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Immune tolerance split between hepatitis B virus precore and core proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Natural history and prognosis of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Treatment options for chronic hepatitis B not responding to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Entecavir for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Dynamics of hepatitis B virus resistance to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.9.913

21 January 2018

Identifiers

DOI

10.1517/14712598.6.9.913

1 reference

15 August 2017

1 reference